Global Gastrointestinal OTC Drugs Market 2015-2019

消化管疾患治療薬(一般用医薬品)の世界市場:胃食道逆流症(GERD)、便秘、下痢、吐気、鼓腸

◆タイトル:Global Gastrointestinal OTC Drugs Market 2015-2019
◆商品コード:IRTNTR5810
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年4月15日
◆ページ数:101
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名使用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、消化管疾患治療薬(一般用医薬品)の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、消化管疾患治療薬(一般用医薬品)の世界市場規模及び予測、治療薬種類別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About gastrointestinal OTC drugs
OTC drugs are medications that do not require a prescription. In contrast, prescription drugs can be sold only to consumers having a legal prescription. OTC drugs are carefully chosen by regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country.

Technavio’s analysts forecast the global gastrointestinal OTC drugs market to grow at a CAGR of 1.48% over the period 2014-2019.

[Covered in this report]
This report covers the present scenario and the growth prospects of the global gastrointestinal OTC drugs market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various OTC drugs available in the market for the management of gastrointestinal disorders such as:
• GERD/Heartburn
• Constipation
• Diarrhea
• Nausea due to motion sickness
• Flatulence

The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also discusses the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.
Technavio’s report, Global Gastrointestinal OTC Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and EMEA and APAC; it also covers the global gastrointestinal OTC drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions
• Americas
• APAC
• EMEA

Key vendors
• Bayer
• GlaxoSmithKline
• Johnson & Johnson
• Perrigo
• Pfizer
• Procter & Gamble

Other prominent vendors
• Abbott
• Boehringer Ingelheim
• C.B. Fleet
• Nestle
• Omega
• Purdue Pharma
• Reckitt Benckiser
• Sanofi
• Teva Pharmaceutical

Market driver
• Increase in patient population
• For a full, detailed list, view our report

Market challenge
• High spending on advertisement
• For a full, detailed list, view our report

Market trend
• Strategic alliances
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market overview
03.2 Product offerings

04.Market Research Methodology
04.1 Market research process
04.2 Research methodology

05.Introduction

06.Overview: OTC Drugs
06.1 Regulatory pathways for OTC approval
06.2 FDA OTC drug approval process
06.2.1 OTC NDA
06.2.2 OTC drug monograph
06.2.3 Gastrointestinal prescription to OTC switch

07.Epidemiology of Gastrointestinal Disorders

08.Market Landscape
08.1 Market overview
08.2 Market size and forecast
08.3 Top predictions
08.4 Five forces analysis

09.Market Segmentation by Therapeutic Class of Drug
09.1.1 Gastric acid reducers
09.1.2 Gastric acid neutralizers
09.1.3 Laxatives
09.1.4 Antidiarrheals
09.1.5 Antiemetics
09.1.6 Others

10.Market Segmentation by Indication
10.1.1 GERD
10.1.2 Constipation
10.1.3 Diarrhea
10.1.4 Nausea caused by motion sickness
10.1.5 Flatulence

11.Geographical Segmentation
11.1 Gastrointestinal OTC drugs market in Americas
11.1.1 Market size and forecast
11.2 Gastrointestinal OTC drugs market in EMEA
11.2.1 Market size and forecast
11.3 Gastrointestinal OTC drugs market in APAC
11.3.1 Market size and forecast

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and their Impact

19.Vendor Landscape
19.1 Competitive scenario
19.1.1 Key news
19.1.2 Mergers and acquisitions
19.2 Market share analysis 2014
19.2.1 Bayer
19.2.2 GlaxoSmithKline
19.2.3 Johnson & Johnson
19.2.4 Perrigo
19.2.5 Pfizer
19.2.6 P&G
19.3 Other prominent vendors

20.Key Vendor Analysis
20.1 Bayer
20.1.1 Key facts
20.1.2 Business overview
20.1.3 Business segmentation by revenue 2014
20.1.4 Business segmentation by revenue 2013 and 2014
20.1.5 Geographical segmentation by revenue 2014
20.1.6 Business strategy
20.1.7 Recent developments
20.1.8 SWOT analysis
20.2 GlaxoSmithKline
20.2.1 Key facts
20.2.2 Business overview
20.2.3 Business segmentation by revenue 2014
20.2.4 Business segmentation by revenue 2013 and 2014
20.2.5 Geographical segmentation by revenue 2014
20.2.6 Business strategy
20.2.7 Recent developments
20.2.8 SWOT analysis
20.3 Johnson & Johnson
20.3.1 Key facts
20.3.2 Business overview
20.3.3 Business segmentation by revenue 2014
20.3.4 Business segmentation by revenue 2013 and 2014
20.3.5 Geographical segmentation by revenue 2014
20.3.6 Business strategy
20.3.7 Recent developments
20.3.8 SWOT analysis
20.4 Perrigo
20.4.1 Key facts
20.4.2 Business overview
20.4.3 Business segmentation by revenue 2014
20.4.4 Business segmentation by revenue 2013 and 2014
20.4.5 Geographical segmentation by revenue 2014
20.4.6 Business strategy
20.4.7 Recent developments
20.4.8 SWOT analysis
20.5 Pfizer
20.5.1 Key facts
20.5.2 Business overview
20.5.3 Business segmentation by revenue 2014
20.5.4 Business segmentation by revenue 2013 and 2014
20.5.5 Geographical segmentation by revenue 2014
20.5.6 Business strategy
20.5.7 Key developments
20.5.8 SWOT analysis
20.6 P&G
20.6.1 Key facts
20.6.2 Business overview
20.6.3 Business segmentation by revenue 2014
20.6.4 Business segmentation by revenue 2013 and 2014
20.6.5 Geographical segmentation by revenue 2014
20.6.6 Business strategy
20.6.7 Recent developments
20.6.8 SWOT analysis

21.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market research methodology
Exhibit 2: Comparison between prescription and OTC drugs
Exhibit 3: Advantages and disadvantages of OTC drugs
Exhibit 4: Ways to establish an OTC drug in different markets
Exhibit 5: Key regulatory bodies for OTC approval
Exhibit 6: FDA OTC drug approval process
Exhibit 7: Comparison of NDA versus OTC monograph process
Exhibit 8: Mechanisms to amend an OTC drug monograph
Exhibit 9: Drugs underwent Rx-to-OTC switch in US
Exhibit 10: Global gastrointestinal OTC drugs market 2014-2019 ($ million)
Exhibit 11: Top predictions in global gastrointestinal OTC drugs market
Exhibit 13: Global gastrointestinal OTC drugs market by therapeutic class of drug
Exhibit 14: Global gastrointestinal OTC drugs market by therapeutic class of drug 2014
Exhibit 15: Global gastrointestinal OTC drugs market by indication
Exhibit 16: Segmentation of global gastrointestinal OTC drugs market by geography 2014
Exhibit 17: Segmentation of global gastrointestinal OTC drugs market by geography 2019
Exhibit 18: Gastrointestinal OTC drugs market in Americas 2014-2019 ($ million)
Exhibit 19: Gastrointestinal OTC drugs market in EMEA 2014-2019 ($ million)
Exhibit 20: Gastrointestinal OTC drugs market in APAC 2014-2019 ($ million)
Exhibit 21: Key takeaways: Bayer
Exhibit 22: Key takeaways: GlaxoSmithKline
Exhibit 23: Key takeaways: Johnson & Johnson
Exhibit 24: Key takeaways: Perrigo
Exhibit 25: Product portfolio matrix of major vendors
Exhibit 26: Key takeaways: Pfizer
Exhibit 27: Key takeaways: P&G
Exhibit 28: Bayer: business segmentation by revenue 2014
Exhibit 29: Bayer: business segmentation by revenue 2013 and 2014 (US$ billion)
Exhibit 30: Bayer: geographical segmentation by revenue 2014
Exhibit 31: GlaxoSmithKline: business segmentation by revenue 2014
Exhibit 32: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 33: GlaxoSmithKline: geographical segmentation by revenue 2014
Exhibit 34: Johnson & Johnson: business segmentation by revenue 2014
Exhibit 35: Johnson & Johnson: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 36: Johnson & Johnson: geographical segmentation by revenue 2014
Exhibit 37: Perrigo: business segmentation by revenue 2014
Exhibit 38: Perrigo: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 39: Perrigo: geographical segmentation by revenue 2014
Exhibit 40: Pfizer: business segmentation by revenue 2014
Exhibit 41: Pfizer: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 42: Pfizer: geographical segmentation by revenue 2014
Exhibit 43: P&G: business segmentation by revenue 2014
Exhibit 44: P&G: business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 45: P&G: geographical segmentation by revenue 2014



【掲載企業】

AG, GlaxoSmithKline plc, Johnson & Johnson Ltd., Perrigo Co. plc, Pfizer Inc. and Procter & Gamble Co., Abbott, Boehringer Ingelheim, C.B. Fleet, Daewoong, Eisai, Nestle, Omega, Purdue Pharma, Reckitt Benckiser, Sanofi, Taisho, Takeda Pharmaceutical and Teva Pharmaceutical.

【資料のキーワード】

消化管疾患治療薬、一般用医薬品(OTC医薬品)、胃食道逆流症(GERD)治療薬、便秘治療薬、下痢治療薬、吐気治療薬、鼓腸治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[消化管疾患治療薬(一般用医薬品)の世界市場:胃食道逆流症(GERD)、便秘、下痢、吐気、鼓腸] (Global Gastrointestinal OTC Drugs Market 2015-2019 / IRTNTR5810)販売に関する免責事項
[消化管疾患治療薬(一般用医薬品)の世界市場:胃食道逆流症(GERD)、便秘、下痢、吐気、鼓腸] (Global Gastrointestinal OTC Drugs Market 2015-2019 / IRTNTR5810)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆